Skip to main content
. 2022 Jan 24;10(1):e003024. doi: 10.1136/jitc-2021-003024

Figure 4.

Figure 4

Patients with melanoma in CR over time. CR rates among patients undergoing immune checkpoint inhibitor therapy steadily increased, indicating that the best response can improve over time.36 40 57 58 CR, complete response; IPI, ipilimumab; NIVO, nivolumab.